Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations
This article was originally published in The Pink Sheet Daily
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.
You may also be interested in...
Alexion plans to use voucher for one of its own products and might be targeting its next-generation version of blockbuster Soliris.
FDA advisory committee will revisit REMS for ultra-rare disease drug as part of larger agency effort to evaluate the effectiveness of the safety programs.
NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.